[go: up one dir, main page]

WO2014035828A3 - Inhibition of axl signaling in anti-metastatic therapy - Google Patents

Inhibition of axl signaling in anti-metastatic therapy Download PDF

Info

Publication number
WO2014035828A3
WO2014035828A3 PCT/US2013/056435 US2013056435W WO2014035828A3 WO 2014035828 A3 WO2014035828 A3 WO 2014035828A3 US 2013056435 W US2013056435 W US 2013056435W WO 2014035828 A3 WO2014035828 A3 WO 2014035828A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibition
axl
axl signaling
metastatic therapy
metastatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/056435
Other languages
French (fr)
Other versions
WO2014035828A2 (en
Inventor
Amato J. Giaccia
Erinn Bruno RANKIN
Jennifer R. Cochran
Douglas Jones
Mihalis Kariolis
Katherine Fuh
Yu MIAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/595,936 external-priority patent/US9074192B2/en
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of WO2014035828A2 publication Critical patent/WO2014035828A2/en
Publication of WO2014035828A3 publication Critical patent/WO2014035828A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
PCT/US2013/056435 2012-08-27 2013-08-23 Inhibition of axl signaling in anti-metastatic therapy Ceased WO2014035828A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/595,936 2012-08-27
US13/595,936 US9074192B2 (en) 2010-01-22 2012-08-27 Inhibition of AXL signaling in anti-metastatic therapy

Publications (2)

Publication Number Publication Date
WO2014035828A2 WO2014035828A2 (en) 2014-03-06
WO2014035828A3 true WO2014035828A3 (en) 2014-05-01

Family

ID=50184586

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/056435 Ceased WO2014035828A2 (en) 2012-08-27 2013-08-23 Inhibition of axl signaling in anti-metastatic therapy

Country Status (1)

Country Link
WO (1) WO2014035828A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148474B (en) * 2014-10-21 2021-07-20 协和麒麟株式会社 Anti-human Gas6 monoclonal antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
WO2011091305A2 (en) * 2010-01-22 2011-07-28 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
WO2011091305A2 (en) * 2010-01-22 2011-07-28 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RANKIN, EB ET AL.: "AXL Is An Essential Factor And Therapeutic Target For Metastatic Ovarian Cancer.", CANCER RESEARCH., vol. 70, no. 19, 21 September 2010 (2010-09-21), pages 7570 - 7579 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148474B (en) * 2014-10-21 2021-07-20 协和麒麟株式会社 Anti-human Gas6 monoclonal antibody

Also Published As

Publication number Publication date
WO2014035828A2 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
WO2011091305A3 (en) Inhibition of axl signaling in anti-metastatic therapy
BR112013011480A8 (en) cancer treatment method, method of enhancing the therapeutic efficacy of an anticancer drug, pmo1183 or a pharmaceutically acceptable salt thereof, use thereof and kit for use in cancer treatment
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
WO2012062925A3 (en) Compounds and methods for treating pain
WO2015095227A3 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016100738A3 (en) Antifibrotic activity of gas6 inhibitor
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MX366899B (en) New compounds.
WO2014012094A3 (en) Tetracycline compounds for treating neurodegenerative disorders
MX349004B (en) New compounds.
MX2015001122A (en) Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor.
WO2014070991A3 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
WO2013188847A8 (en) Compositions and methods for transmucosal absorption
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
IN2015MN00001A (en)
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
EP3421039A4 (en) Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor
CA2908957C (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
MX339243B (en) Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof.
NZ716765A (en) Pharmaceutical combinations for the treatment of cancer
MX2020007130A (en) Methods of treating metastatic cancers using axl decoy receptors.
PT2846770T (en) Intrathecal administration of mtor inhibitors for the therapy of neurodegenerative, neuroinflammatory and neurooncologic diseases
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
WO2013131089A3 (en) Potent anticancer activity via dual compound activation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13832822

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13832822

Country of ref document: EP

Kind code of ref document: A2